# Veran Medical Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/veran-medical-technologies

- Industry: Medical Devices & Equipment
- Headquarters: St. Louis, US
- Website: www.veranmedical.com
- Total disclosed funding: $4.8M
- Latest round: Series A (May 12, 2008)
- Investors on record: 2

## About

Veran Medical Technologies, Inc. is a specialized healthcare company focused on providing innovative Human Growth Hormone (HGH) products to address growth hormone deficiencies in adults, enhancing their overall health and physical performance.Founded in 2005 and headquartered in St. Louis, US, Veran Medical Technologies, Inc. specializes in the development and sale of HGH therapies. The company was acquired by Olympus Corporation in December 2020 for USD 340 mn from various venture capital firms. Jason Pesterfield serves as CEO, overseeing the company's strategic operations.Veran Medical Technologies offers a range of high-quality injectable Human Growth Hormone (HGH) products, including Somatropin, Zptropin, and Genotropin. These products are designed to support adults facing growth hormone deficiencies, addressing issues such as weight gain and decreased bone density. Their offerings are targeted toward a diverse customer base, including fitness enthusiasts and individuals seeking anti-aging solutions, primarily in North America and Europe.The company generates revenue through direct sales of HGH products via its online platform, enabling customers to purchase various HGH brands at competitive prices. This sales model emphasizes individual transactions without subscription services, catering to different budgets while maintaining product quality.Following its acquisition by Olympus Corporation in December 2020, which was aimed at expanding Olympus's business, Veran Medical Technologies plans to innovate new HGH product offerings and explore expansion into international markets. The recent funding of USD 340 mn will support these initiatives, allowing the company to leverage Olympus's global reach and resources effectively.

## Funding rounds

- Series A, May 12, 2008, $4.8M — Advantage Capital, Prolog Ventures

## Investors

- Advantage Capital — Series A
- Prolog Ventures (https://capitalatlas.ai/funds/prolog-ventures) — Series A